ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Dr Michael Snabes is the only one of Abbvie’s Sr Director’s , VP, SVP a EVP who does not have a Linkedin profile. Odd seeing that upon getting hired as Abbvie’s Sr Medical Director of Men and Women’s Health he had a Linkedin profile showing he had moved from BPAX to Abbvie and for some reason shortly afterward he took down his Linkedin account. (Why only Snabes? Something to hide?)

August 2015 CVR’s start showing up in trading accounts. They had been a book entry recorded June 2013 with no record provided to shareholders until now. (Why spend the money if there was no movement on Libigel?)

Abbvie picked up the $350 Priority Review Voucher from United TherapeuticsIsuued (March 10, 2015). August 19th , 2015 the day after Addyi was approved. (I wonder if Dr Louis W. Sullivan swho hasserved on United Therapeutics BOD since 2002 and was Chairman of the BOD for Bosante Libigel development and Merger with ANIP, a hormone manufacturer with large capacity was influential in the PRV acquisition?)

December 19, 2015 patent prosecution adds claims that restoring t-levels reduces risk of Breast Cancer.

May 31, 2016, last patient of 3656 patients completed FDA’s 5 year follow up requirement.

Libigel no longer advertised as an opportunity on AVARX. Even when listed, it never added the CV or Breast Cancer Risk reduction. Last updated Feb 22, 2016. Therefore never publicly shopped around.

Three new patent application have been submitted maintaining continuity of data. Should be some revealing information in the specifications.
ANIP let’s Libigel trademark expire.

To add color to the value of Libigel and the CV discovery:
By 2023 the dyslipidemia market is expected to grow to $37.9 billion with 85.5 % of the market covered by Anip licencing rights.
Dyslipidemia Maket

By 2020, the global hypertension market will be $32 billion.
Hypertension Market

Global Breast Cancer Market is expected to reach $17.2 billion by 2021
Breast Cancer Market

In each of the above global markets, a sizabkle percentage would inlcude post menopausal women.

Pfizer recently acquired Anacor for $5.2 billion. Anacor had one approved product, Kerydin with projected peak sales of $1 Billion which the split 50/50 with Sandoz and a recent NDA filing for Crisaborole with projected peak sales of $1.7 billion. This total projected peak sales of $2.2 billion. Libigel blows this out of the water just by physicians switching existing off label and compounded testosterone prescriptions.
[url]
seekingalpha.com/article/3815966-anacor-pharmaceuticals-expensive[/url][tag]Anacor deal[/tag]